Mega Genomics AAQS

Que fait Mega Genomics ? Mega Genomics Ltd, listed on the Hong Kong Stock Exchange under ticker 6667.HK with ISIN KYG5960G1047, is a health care company headquartered in Beijing, China. The company, which went public on June 22, 2022, employs 267 full-time staff. Mega Genomics operates as a genetic testing platform, offering consumer genetic testing and cancer screening services. Its business is structured into three segments. The Consumer Genetic Testing Services segment provides tests related to nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing, and infectious disease testing. The Cancer Screening Services segment offers specific tests including the Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test, and the ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment delivers genetic research and analysis services to third-party research institutions. The company's website is https://www.megagenomics.cn/. Mega Genomics focuses on providing genetic testing solutions for both consumer and clinical applications, with an emphasis on cancer-related screening and personalized health assessments. The company's operations are based in Beijing, reflecting its position within China's growing health care sector. As a publicly traded entity, Mega Genomics is subject to the regulatory requirements of the Hong Kong Stock Exchange. Mega Genomics est l'une des entreprises les plus populaires sur Eulerpool.